(1) May authorize:

(i) For protocols by a licensed physician and licensed pharmacist, the initiation of drug therapy under written, disease-state specific protocols;

(ii) The modification, continuation, and discontinuation of drug therapy under written, disease-state specific protocols;

(iii) The ordering of laboratory tests; and

(iv) Other patient care management measures related to monitoring or improving the outcomes of drug or device therapy; and

(2) May not authorize acts that exceed the scope of practice of the parties to the therapy management contract.

(b) A protocol shall prohibit the substitution of a chemically dissimilar drug product by the pharmacist for the product prescribed by the authorized prescriber, unless permitted in the therapy management contract.